Fas expression might reinforce the immune privilege of apoptosis-resistant tumor cells, which, in most cases, express low levels of Fas and thus, cannot sufficiently respond to apoptotic signal brought about by FasL in immune cells (Nagata, 1999; Strasser et al., 2009; Zhou et al., 1998). The gene discussed is FASLG; the disease is neoplasm.